17,261 trials
Advanced Soft Tissue Sarcoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 3; 1; 22 Participants
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Glioma
Primary: Progression-free Survival
Breast Cancer
Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL
CD19+ Diffuse Large B-cell Lymphomas · Follicular Lymphomas · Mantle Cell Lymphomas
Primary: Dose-limiting Toxicity — 8.33 percentage of subjects
Clostridium Difficile Infection
Primary: Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks — 112; 23; 30; 52 Participants
Non-Small Cell Lung Cancer
Primary: Time to Progression-Free Survival (PFS) — 7.9 months
Gastric or Gastroesophageal Junction Adenocarcinoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Phase 1b — 6; 2 Participants
Otomycosis
Primary: Primary Efficacy Endpoint — 1; 3; 1 Participants
Systemic Sclerosis · Scleroderma
Primary: Number of Participants Who Experience Grade 3 or Higher Adverse Events That Occur at or Before Week 24 — 0; 0 Participants
Lung Cancer · Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Primary: Overall Response Rate — 18; 1; 5; 12 Participants
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Diffuse Well-differentiated Lymphocytic Lymphoma
Primary: Number of Subjects With Adverse Events — 199 Participants
Solid Tumor
Primary: Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs — 9; 9; 11; 9 Participants
Atopic Dermatitis
Primary: Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16 — 83.7; 83.3 Percentage of participants
Cancer of Prostate · Cancer of the Prostate · Neoplasms, Prostate
Primary: Percentage of Patients to Successfully Generate and Administer the Alpha-DC1 Vaccine — 100; 100 percentage of participants